Fennec Pharmaceuticals (NASDAQ: FENC) sells PEDMARK, the only FDA-approved drug to prevent cisplatin-induced hearing loss in pediatric cancer patients. The stock dropped 19% on March 25, 2026 after reporting record revenue but missing EPS estimates. Separately, a patent settlement filed nine days earlier extended the company's monopoly window by seven years.

What the Filing Says

FENC's FY2025 8-K (March 24, 2026) is an earnings release. The numbers tell two stories depending on which line you read.

The revenue story is strong. FY2025 net product sales hit $44.6M, up 50% from $29.6M. Q4 alone was $13.8M, up 75% year-over-year, with record patient enrollments and conversion rates. Growth came from both new and existing accounts. The Q4 run rate annualizes to ≈$55M.

The profitability story is weak. FY2025 operating loss was $6.7M, worse than FY2024's $2.6M operating income. G&A expenses ballooned to $28.8M (64% of revenue), driven by IP legal costs, headcount, and equity compensation. Q4 net loss included a $2.0M one-time charge for paying off all company debt. EPS was -$0.17 versus the $0.04 consensus estimate.

Both stories are true simultaneously. The company is growing fast but spending faster.

The balance sheet, however, is clean. Zero debt (paid down $21.5M in November 2025). $36.8M cash. Shareholders' equity flipped from a $5.9M deficit to $35.1M positive, funded by a $42M oversubscribed equity offering. At current operating losses (≈$7-10M/year), runway is 3.5-5 years without another raise, assuming revenue covers its share.

Gross margins are 91.6%. COGS grew 18% while revenue grew 50%. The product economics are exceptional. Every $10M in incremental revenue drops ≈$9.1M to gross profit. The question is entirely about the overhead below the gross margin line.

A separate 8-K filed March 16 disclosed that Fennec settled patent litigation with Cipla, blocking generic entry until September 1, 2033. Cipla was the only ANDA challenger. Combined with patent protection to 2039 and Orphan Drug Exclusivity, this creates a layered IP moat: no generic until 2033, no patent expiry until 2039, no orphan exclusivity lapse for years beyond that.

On the clinical side: Japan's STS-J01 Phase 2/3 trial reported positive topline results in December 2025 (hearing loss rates of 16-24% versus 56-63% historical). Fennec is pursuing Japan registration and seeking a licensing partner. Adult-population studies are underway at City of Hope (metastatic testicular GCT) and Tampa General (AYA/adult real-world use), with a 15-patient HNC retrospective presented in February 2026. These are investigator-initiated — not company-sponsored registrational trials. The path from these studies to an FDA-approved adult label is 5-8 years.

Norgine, which licenses PEDMARK (as PEDMARQSI) in Europe and the UK, has launched in the UK and Germany with what the CFO called "significant traction." Royalties run mid-teens to mid-twenties percent of net sales, with milestones pending for German pricing and aggregate sales thresholds. EU5 rollout (Italy, Spain, France, Nordics) is planned through early 2026.

What the Market Thinks

At $6.02, FENC trades at:

• 3.4x trailing EV/revenue ($151M EV on $44.6M)
• 2.7x forward EV/revenue on the Q4 annualized run rate (≈$55M)
• 26th percentile of its 52-week range ($4.68-$9.92)
• RSI 23.5, deeply oversold, on 5x normal volume

Six analysts cover the stock. All have Buy ratings. Mean price target is $15.17, median $15.50 — implying 150% upside from current levels. The most recent target (Piper Sandler, January 2026) is $18.

The stock is back to where it was twelve months ago. Revenue grew 50% in that time. XBI (the biotech sector ETF) returned +37.5% over the same period. Factor regression shows FENC's XBI beta is 0.77, so the stock should have captured roughly 29% from sector alone. Instead, FENC delivered +12.9% pre-earnings, now -6% post-earnings. The idiosyncratic underperformance is ≈32 percentage points.

Backing out scenario probabilities from the current price, the market appears to assign 75-80% probability to a bear case (revenue stalls below $50M, multiple compresses to 2.5x, stock goes to ≈$4.80). It assigns roughly 5-10% probability to the acceleration case (revenue reaches $60M+, profitability visible, stock re-rates to $13+).

CEO Jeff Hackman bought 13,710 shares at ≈$6.02 on February 18. The CFO has been converting options, not selling. Insider activity is net positive at small scale.

Why the Gap Exists

Four specific reasons the market may be mispricing this:

1. The EPS miss obscures the revenue beat. Q4 EPS of -$0.17 versus +$0.04 expected is a headline disaster. But $2.0M of the miss is a non-recurring debt extinguishment charge (the company paid off ALL its debt — this is good news reported as bad news). Another chunk is the G&A step-up from patent defense against Cipla, which resulted in the settlement that extended the monopoly. The market reacted to the -$0.17 headline. The counterparty on the sell side is likely retail and quantitative models triggering on the miss, not informed sellers with a thesis that the monopoly is breaking.

2. The Cipla settlement is nine days old and in a separate filing. The March 16 8-K blocking generic entry until 2033 is a material positive that many investors may not have connected to the March 24 earnings release. Patent settlements don't generate headlines the way earnings misses do. The practical effect is that FENC's monopoly window is now at minimum seven years, extending beyond what most analysts had modeled.

3. Cisplatin displacement risk is overstated. Cross-ticker verification using AstraZeneca and Merck Q4 2025 transcripts confirms that immunotherapy is combining WITH cisplatin (the NIAGARA bladder cancer trial), not replacing it. Cisplatin-alternative therapies target cisplatin-INELIGIBLE patients. The global cisplatin market is growing at 5-9% CAGR. PEDMARK may actually reinforce cisplatin's standard-of-care position by mitigating its worst side effect.

4. Micro-cap, single-product discount is legitimate but excessive at 3x revenue. A single-product company with no pipeline deserves a discount. But comparable rare disease monopolies (Kiniksa/ARCALYST at a similar stage) traded at 4-8x revenue while growing at comparable rates. FENC at 2.7x forward revenue is pricing in sustained execution failure, not merely single-product risk.

Risks

1. Q4 was a seasonal peak (HIGH impact, resolves May 12). If Q1 2026 revenue comes in below $12M, the +75% Q4 growth was a one-quarter anomaly. This is the single biggest risk to the thesis. Pediatric oncology enrollment may follow academic-year patterns. We assign 50% probability to Q1 exceeding $14M, which is an honest admission that we cannot resolve this from the filing alone.

2. G&A never levers (HIGH impact, resolves over 2-4 quarters). At $28.8M G&A on $44.6M revenue, the overhead structure is bloated. If G&A grows proportionally with revenue, FENC never reaches profitability without another dilutive raise. The bear case depends on this. The non-cash equity compensation component is unknown — if material, true cash G&A is lower than reported, and breakeven is closer.

3. Single-product concentration (MEDIUM impact, permanent). FENC has no pipeline beyond PEDMARK. A safety signal, however unlikely for a therapy approved since 2022, would be catastrophic. There is no second act. This is the risk you accept for the monopoly premium.

4. XBI beta instability (MEDIUM impact, continuous). FENC's rolling 60-day beta to XBI ranges from 0.52 to 1.36. In a biotech sector correction, the realized beta could spike. At the high end, a 20% XBI drawdown would hit FENC for ≈26% from sector alone, compounding any idiosyncratic weakness. XBI is currently at the 81st percentile of its 52-week range with elevated implied volatility.

5. Dilution (LOW-MEDIUM impact, conditional). The $42M raise is done. At $36.8M cash and $7-10M annual operating losses, another raise isn't imminent. But if growth disappoints AND expenses don't moderate, a 2027 raise at depressed prices becomes likely.

Catalysts

• Q1 2026 earnings (May 12, 2026): THE decision point. Revenue above $14M confirms acceleration. Below $12M challenges the thesis. Forty-eight days away.
• Analyst updates (late March-April 2026): Six analysts with Buy ratings and $13-18 targets will respond to the 19% drop. Reaffirmations signal conviction; downgrades signal the market is right.
• Japan partnership announcement (2026 H2, 35% probability): A licensing deal with upfront milestone ($10-30M estimated) would validate the international thesis and provide non-dilutive cash.
• Norgine milestones (2026): German final pricing and aggregate EU sales milestones are pending. Each triggers a payment to FENC.
• FY2026 full-year results (Q1 2027): Resolves the commercial ramp thesis definitively. Revenue above $55M at improving operating margins closes the estimate gap.

What Would Change Our Mind

• Q1 2026 revenue below $12M. This would mean Q4 was a peak, not a ramp. Our base case (40%) assumes at least $54M FY2026 revenue, which requires quarterly revenue above $13M. A sharp Q1 miss would shift probability mass from acceleration to stall.
• Another equity offering announced before operating profitability is visible. Management just raised $42M and paid off all debt. Going back to the market before showing leverage would signal that the cost structure is structural, not transitional.
• A competitor entering Phase 2 for cisplatin ototoxicity prevention. Currently the nearest threat (Regeneron's DB-020) is Phase 1b and focused on adults. If DB-020 or another agent advances to Phase 2 with promising data, the monopoly duration thesis weakens.
• Cisplatin removed from NCCN guidelines for a major pediatric tumor type. The TAM depends on cisplatin remaining standard-of-care. Cross-ticker evidence says this isn't happening, but a guideline change would be immediate and material.
• Earnings call transcript reveals management guiding below $50M FY2026 revenue. We have not read the March 24 conference call. If management's own guidance contradicts the Q4 trajectory, the filing-based thesis is wrong.

Evidence